Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor

International Journal of Environmental Research and Public Health

Volumn 9, Issue 7, 2012, Pages 2444-2453

  Ezoe, Sachiko ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Etoposide; MLL; Secondary leukemia; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DAURINOL; DOXORUBICIN; EPIPODOPHYLLOTOXIN; ETOPOSIDE; IFOSFAMIDE; MIXED LINEAGE LEUKEMIA PROTEIN; UNCLASSIFIED DRUG;

BLOOD SYSTEM DISORDER; CANCER; CHEMOTHERAPY; CHROMOSOME; INHIBITOR; MEDICINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DNA DAMAGE; DRUG DOSE COMPARISON; DRUG MEGADOSE; EWING SARCOMA; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; GENOTOXICITY; HUMAN; LEUKEMOGENESIS; LOW DRUG DOSE; METASTASIS; MIXED LINEAGE LEUKEMIA GENE; NONHUMAN; OVERALL SURVIVAL; STEM CELL TRANSPLANTATION; TESTIS CANCER; TUMOR GENE;

EID: 84863867276     PISSN: None     EISSN: 16604601     Source Type: Journal    
DOI: 10.3390/ijerph9072444     Document Type: Article

References (55)

1. Hande, K.R. Etoposide: Four decades of development of a topoisomerase II inhibitor. Eur. J. Cancer 1998, 34, 1514-1521.
2. Ratain, M.J.; Kaminer, L.S.; Bitran, J.D.; Larson, R.A.; Le Beau, M.M.; Skosey, C.; Purl, S.; Hoffman, P.C.; Wade, J.; Vardiman, J.W.; et al. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood 1987, 70, 1412-1417.
3. Potzsch, C.; Fetscher, S.; Mertelsmann, R.; Lubbert, M. Acute myelomonocytic leukemia secondary to synchronous carcinomas of the breast and lung, and to metachronous renal cell carcinoma. J. Cancer Res. Clin. Oncol. 1997, 123, 678-680.
4. Shearer, P.; Kapoor, G.; Beckwith, J.B.; Takashima, J.; Breslow, N.; Green, D.M. Secondary acute myelogenous leukemia in patients previously treated for childhood renal tumors: A report from the National Wilms Tumor Study Group. J. Pediatr. Hematol. Oncol. 2001, 23, 109-111.
5. Domer, P.H.; Head, D.R.; Renganathan, N.; Raimondi, S.C.; Yang, E.; Atlas, M. Molecular analysis of 13 cases of MLL/11q23 secondary acute leukemia and identification of topoisomerase II consensus-binding sequences near the chromosomal breakpoint of a secondary leukemia with the t(4;11). Leukemia 1995, 9, 1305-1312.
6. Levine, E.G.; Bloomfield, C.D. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin. Oncol. 1992, 19, 47-84.
7. Kollmannsberger, C.; Hartmann, J.T.; Kanz, L.; Bokemeyer, C. Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies. J. Cancer Res. Clin. Oncol. 1998, 124, 207-214.
8. Kaneko, Y.; Maseki, N.; Sakurai, M.; Shibuya, A.; Shinohara, T.; Fujimoto, T.; Kannno, H.; Nishikawa, A. Chromosome pattern in juvenile chronic myelogenous leukemia, myelodysplastic syndrome, and acute leukemia associated with neurofibromatosis. Leukemia 1989, 3, 36-41.
9. Felix, C.A. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim. Biophys. Acta 1998, 1400, 233-255.
10. Hayes, J.D.; Pulford, D.J. The glutathione S-transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit. Rev. Biochem. Mol. Biol. 1995, 30, 445-600.
11. Willman, C.L.; Sever, C.E.; Pallacicini, M.G.; Harada, H.; Tanaka, N.; Slovak, M.L.; Yamamoto, H.; Harada, K.; Meeker, T.C. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 1993, 259, 968-971.
12. Le Beau, M.M.; Espinosa, R., 3rd.; Neuman, W.L.; Stock, W.; Roulston, D.; Larson, R.A.; Keinanen, M.; Westbrook, C.A. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc. Natl. Acad. Sci. USA 1993, 90, 5484-5488.
13. Pui, C.H. Epipodophyllotoxin-related acute myeloid leukaemia. Lancet 1991, 338, doi:10.1016/0140-6736(91)92779-2.
14. Sandler, E.S.; Friedman, D.J.; Mustafa, M.M.; Winick, N.J.; Bowman, W.P.; Buchanan, G.R. Treatment of children with epipodophyllotoxin-induced secondary acute myeloid leukemia. Cancer 1997, 79, 1049-1054.
15. Rimmer, Y.; Chester, J.; Joffe, J.; Stark, D.; Shamash, J.; Powles, T.; White, J.; Wason J.; Parashar, D.; Armstrong, G.; Mazhar, D.; Williams, M.V. Accelerated BEP: A phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour. Br. J. Cancer 2011, 105, 766-772.
16. Bajetta, E.; di Bartolomeo, M.; Carnaghi, C.; Buzzoni, R.; Mariani, L.; Gebbia, V.; Comella, G.; Pinotti, G.; Ianniello, G.; Schieppati, G.; Bochicchio, A.M.; Maiorino, L. FEP regimen (epidoxorubicin, etoposide and cisplatin) in advanced gastric cancer, with or without low-dose GM-CSF: An Italian Trial in Medical Oncology (ITMO) study. Br. J. Cancer 1998, 77, 1149-1154.
17. Pui, C.H.; Ribeiro, R.C.; Hancock, M.L.; Rivera, G.K.; Evans, W.E.; Raimondi, S.C.; Head, D.R.; Behm, F.G.; Mahmoud, M.H.; Sandlund, J.T. et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N. Engl. J. Med. 1991, 325, 1682-1687.
18. Heyn, R.; Khan, F.; Ensign, L.G.; Donaldson, S.S.; Ruymann, F.; Smith, M.A.; Vietti, T.; Maurer, H.M. Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on Intergroup Rhabdomyosarcoma Study III: An interim report. Med. Pediatr. Oncol. 1994, 23, 99-106.
19. Smith, M.A.; Rubinstein, L.; Ungerleider, R.S. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: Estimating the risks. Med. Pediatr. Oncol. 1994, 23, 86-98.
20. Kollmannsberger, C.; Beyer, J.; Droz, J.P.; Harstrick, A.; Hartmann, J.T.; Biron, P.; Flechon, A.; Schoffski, P.; Kuczyk, M.; Schmoll, H.J.; et al. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J. Clin. Oncol. 1998, 16, 3386-3391.
21. Chen, C.L.; Fuscoe, J.C.; Liu, Q.; Pui, C.H.; Mahmoud, H.H.; Relling, M.V. Relationship between cytotoxicity and site-specific DNA recombination after in vitro exposure of leukemia cells to etoposide. J. Natl. Cancer Inst. 1996, 88, 1840-1847.
22. Pedersen-Bjergaard, J.; Daugaard, G.; Hansen, S.W.; Philip, P.; Larsen, S.O.; Rorth, M. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 1991, 338, 359-363.
23. Bokemeyer, C.; Schmoll, H.J.; Kuczyk, M.A.; Beyer, J.; Siegert, W. Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer. J. Natl. Cancer Inst. 1995, 87, 58-60.
24. Boshoff, C.; Begent, R.H.; Oliver, R.T.; Rustin, G.J.; Newlands, E.S.; Andrews, R.; Skelton, M.; Holden, L.; Ong, J. Secondary tumours following etoposide containing therapy for germ cell cancer. Ann. Oncol. 1995, 6, 35-40.
25. Sullivan, D.M.; Glisson, B.S.; Hodges, P.K.; Smallwood-Kentro, S.; Ross, W.E. Proliferation dependence of topoisomerase II mediated drug action. Biochemistry 1986, 25, 2248-2256.
26. Clark, P.I. Clinical pharmacology and schedule dependency of the podophyllotoxin derivatives. Semin. Oncol. 1992, 19, 20-27.
27. Sugita, K.; Furukawa, T.; Tsuchida, M.; Okawa, Y.; Nakazawa, S.; Akatsuka, J.; Ohira, M.; Nishimura, K. High frequency of etoposide (VP-16)-related secondary leukemia in children with non-Hodgkin's lymphoma. Am. J. Pediatr. Hematol. Oncol. 1993, 15, 99-104.
28. Houck, W.; Abonour, R.; Vance, G.; Einhorn, L.H. Secondary leukemias in refractory germ cell tumor patients undergoing autologous stem-cell transplantation using high-dose etoposide. J. Clin. Oncol. 2004, 22, 2155-2158.
29. Baker, D.L.; Schmidt, M.L.; Cohn, S.L.; Maris, J.M.; London, W.B.; Buxton, A.; Stram, D.; Castleberry, R.P.; Shimada, H.; Sandler, A.; et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N. Engl. J. Med. 2010, 363, 1313-1323.
30. Bhatia, S.; Krailo, M.D.; Chen, Z.; Burden, L.; Askin, F.B.; Dickman, P.S.; Grier, H.E.; Link, M.P.; Meyers, P.A.; Perlman, E.J.; et al. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group. Blood 2007, 109, 46-51.
31. Broeker, P.L.; Super, H.G.; Thirman, M.J.; Pomykala, H.; Yonebayashi, Y.; Tanabe, S.; Zeleznik-Le, N.; Rowley, J.D. Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: Correlation with scaffold attachment regions and topoisomerase II consensus binding sites. Blood 1996, 87, 1912-1922.
32. Hess, J.L. MLL: A histone methyltransferase disrupted in leukemia. Trends Mol. Med. 2004, 10, 500-507.
33. Ernst, P.; Fisher, J.K.; Avery, W.; Wade, S.; Foy, D.; Korsmeyer, S.J. Definitive hematopoiesis requires the mixed-lineage leukemia gene. Dev. Cell 2004, 6, 437-443.
34. Hess, J.L.; Yu, B.D.; Li, B.; Hanson, R.; Korsmeyer, S.J. Defects in yolk sac hematopoiesis in Mll-null embryos. Blood 1997, 90, 1799-1806.
35. Yokoyama, A.; Somervaille, T.C.; Smith, K.S.; Rozenblatt-Rosen, O.; Meyerson, M.; Cleary, M.L. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 2005, 123, 207-218.
36. Strissel, P.L.; Strick, R.; Rowley, J.D.; Zeleznik-Le, N.J. An in vivo topoisomerase II cleavage site and a DNase I hypersensitive site colocalize near exon 9 in the MLL breakpoint cluster region. Blood 1998, 92, 3793-3803.
37. Aplan, P.D.; Chervinsky, D.S.; Stanulla, M.; Burhans, W.C. Site-specific DNA cleavage within the MLL breakpoint cluster region induced by topoisomerase II inhibitors. Blood 1996, 87, 2649-2658.
38. Lovett, B.D.; Lo Nigro, L.; Rappaport, E.F.; Blair, I.A.; Osheroff, N.; Zheng, N.; Megonigal, M.D.; Williams, W.R.; Nowell, P.C.; Felix, C.A. Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation. Proc. Natl. Acad. Sci. USA 2001, 98, 9802-9807.
39. Lovett, B.D.; Strumberg, D.; Blair, I.A.; Pang, S.; Burden, D.A.; Megonigal, M.D.; Rappaport, E.F.; Rebbeck, T.R.; Osheroff, N.; Pommier, Y.G.; et al. Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints. Biochemistry 2001, 40, 1159-1170.
40. Stanulla, M.; Wang, J.; Chervinsky, D.S.; Thandla, S.; Aplan, P.D. DNA cleavage within the MLL breakpoint cluster region is a specific event which occurs as part of higher-order chromatin fragmentation during the initial stages of apoptosis. Mol. Cell. Biol. 1997, 17, 4070-4079.
41. Stanulla, M.; Chhalliyil, P.; Wang, J.; Jani-Sait, S.N.; Aplan, P.D. Mechanisms of MLL gene rearrangement: Site-specific DNA cleavage within the breakpoint cluster region is independent of chromosomal context. Hum. Mol. Genet. 2001, 10, 2481-2491.
42. Betti, C.J.; Villalobos, M.J.; Diaz, M.O.; Vaughan, A.T. Apoptotic triggers initiate translocations within the MLL gene involving the nonhomologous end joining repair system. Cancer Res. 2001, 61, 4550-4555.
43. Betti, C.J.; Villalobos, M.J.; Diaz, M.O.; Vaughan, A.T. Apoptotic stimuli initiate MLL-AF9 translocations that are transcribed in cells capable of division. Cancer Res. 2003, 63, 1377-1381.
44. Libura, J.; Slater, D.J.; Felix, C.A.; Richardson, C. Therapy-related acute myeloid leukemia-like MLL rearrangements are induced by etoposide in primary human CD34+ cells and remain stable after clonal expansion. Blood 2005, 105, 2124-2131.
45. Blanco, J.G.; Edick, M.J.; Relling, M.V. Etoposide induces chimeric Mll gene fusions. FASEB J. 2004, 18, 173-175.
46. Bueno, C.; Catalina, P.; Melen, G.J.; Montes, R.; Sanchez, L.; Ligero, G.; Garcia-Perez, J.L.; Menendez, P. Etoposide induces MLL rearrangements and other chromosomal abnormalities in human embryonic stem cells. Carcinogenesis 2009, 30, 1628-1637.
47. Vlasova, I.I.; Feng, W.H.; Goff, J.P.; Giorgianni, A.; Do, D.; Gollin, S.M.; Lewis, D.W.; Kagan, V.E.; Yalowich, J.C. Myeloperoxidase-dependent oxidation of etoposide in human myeloid progenitor CD34+ cells. Mol. Pharmacol. 2011, 79, 479-487.
48. Cowell, I.G.; Sondka, Z.; Smith, K.; Lee, K.C.; Manville, C.M.; Sidorczuk-Lesthuruge, M.; Rance, H.A.; Padget, K.; Jackson, G.H.; Adachi, N.; et al. Model for MLL translocations in therapy-related leukemia involving topoisomerase IIbeta-mediated DNA strand breaks and gene proximity. Proc. Natl. Acad. Sci. USA 2012, 109, 8989-8994.
49. Willmore, E.; de Caux, S.; Sunter, N.J.; Tilby, M.J.; Jackson, G.H.; Austin, C.A.; Durkacz, B.W. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood 2004,103, 4659-4665.
50. Toyoda, E.; Kagaya, S.; Cowell, I.G.; Kurosawa, A.; Kamoshita, K.; Nishikawa, K.; Iiizumi, S.; Koyama, H.; Austin, C.A.; Adachi, N. NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform. J. Biol. Chem. 2008, 283, 23711-23720.
51. Adachi, N.; Suzuki, H.; Iiizumi, S.; Koyama, H. Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: Implications for the repair of topoisomerase II-mediated DNA damage. J. Biol. Chem. 2003, 278, 35897-35902.
52. Shiloh, Y. ATM and related protein kinases: Safeguarding genome integrity. Nat. Rev. Cancer 2003, 3, 155-168.
53. Sun, J.; Oma, Y.; Harata, M.; Kono, K.; Shima, H.; Kinomura, A.; Ikura, T.; Suzuki, H.; Mizutani, S.; Kanaar, R.; Tashiro, S. ATM modulates the loading of recombination proteins onto a chromosomal translocation breakpoint hotspot. PLoS One 2010, 5, doi:10.1371/journal.pone.0013554.
54. Kang, K.; Oh, S.H.; Yun, J.H.; Jho, E.H.; Kang, J.H.; Batsuren, D.; Tunsag, J.; Park, K.H.; Kim, M.; Nho, C.W. A novel topoisomerase inhibitor, daurinol, suppresses growth of HCT116 cells with low hematological toxicity compared to etoposide. Neoplasia 2011, 13, 1043-1057.
55. Hoeksema, K.A.; Jayanthan, A.; Cooper, T.; Gore, L.; Trippett, T.; Boklan, J.; Arceci, R.J.; Narendran, A. Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia. Onco Targets Ther. 2011, 4, 149-168.